Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a market approval filing to the National Medical Products Administration (NMPA) in China for its in-licensed daxibotulinumtoxin A for injection (RT002). The drug has been filed for use in adult cervical dystonia, marking a significant step in expanding its therapeutic portfolio.
Licensing Deal with Revance Therapeutics and Regional Rights
Fosun struck a licensing deal with US firm Revance Therapeutics Inc. in December 2018, obtaining exclusive use, import, and sales rights to RT002 in mainland China, Hong Kong, and Macau. This strategic partnership highlights Fosun’s commitment to bringing innovative medical aesthetics and therapeutic products to the Chinese market.
Daxibotulinumtoxin A as a Long-Acting Nerve Regulator
The long-acting nerve regulator, featuring daxibotulinumtoxin A as the active pharmaceutical ingredient, serves both as a medical aesthetics product and a therapeutic product. It was approved for improving moderate to severe frown lines in the US in September 2022. This indication was accepted for review by the NMPA in April 2023, indicating the potential for RT002 to be used in aesthetic and therapeutic applications in China.-Fineline Info & Tech
